atrasentan has been researched along with Androgen-Independent Prostatic Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ely, B; Gertz, E; Goldkorn, A; Hussain, M; Lara, PN; Mack, PC; Quinn, DI; Tangen, C; Thompson, IM; Twardowski, PW; Van Loan, MD; Vogelzang, NJ | 1 |
| Chen, M; He, ZH; Qi, P; Song, RX; Wang, ZP; Zhang, LX | 1 |
1 review(s) available for atrasentan and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Disease-Free Survival; Docetaxel; Endothelin A Receptor Antagonists; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Pyrrolidines; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2015 |
1 trial(s) available for atrasentan and Androgen-Independent Prostatic Cancer
| Article | Year |
|---|---|
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Amino Acids; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Biomarkers, Tumor; Bone Neoplasms; Bone Remodeling; Collagen Type I; Disease-Free Survival; Docetaxel; Double-Blind Method; Endothelin A Receptor Antagonists; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Peptide Fragments; Peptides; Predictive Value of Tests; Procollagen; Prognosis; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Pyrrolidines; ROC Curve; Taxoids; Treatment Failure | 2014 |